Literature DB >> 12116041

Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination.

Alfonso Mele1, Tommaso Stroffolini, Alessandro R Zanetti.   

Abstract

In Italy, a program of vaccination against hepatitis B targeted at the immunisation of persons at high risk began in 1983. In 1991, vaccination became mandatory for all newborns and adolescents. Since then, the vaccine has been given to more than 10 million children, with an outstanding record of safety and efficacy. The coverage rate is globally around 94%, with differences between the Northern and Southern regions, with the latter having the lower acceptance rate. According to the National Surveillance System (SEIEVA), the incidence of acute hepatitis B per 10(5) inhabitants declined from 5.4 in 1990 to 2 in 2000. The reduction was even greater among 15-24-year-old individuals, where the incidence rate per 10(5) decreased from 17.3 to 2 in the same period. In parallel with the decline of hepatitis B, hepatitis delta has also declined significantly. Catch-up immunisation of unvaccinated adolescents, as well as an effort to improve the vaccination coverage rate in high-risk groups, are required to ameliorate the efficacy of the vaccination campaign. Routine administration of booster doses of vaccine is not considered necessary to sustain immunity in immunocompetent persons. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116041     DOI: 10.1002/jmv.10092

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

Review 1.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

2.  Long term protection after hepatitis B vaccination.

Authors:  Sandra Puvacić; Jelena Ravlija; Zlatko Puvacić; Ivan Curić
Journal:  Bosn J Basic Med Sci       Date:  2005-08       Impact factor: 3.363

Review 3.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 4.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Acute hepatitis B in the era of immunisation: pitfalls in the identification of high risk patients.

Authors:  G Rosner; Y Lurie; L Blendis; Z Halpern; R Oren
Journal:  Postgrad Med J       Date:  2006-03       Impact factor: 2.401

6.  Long-term immune protection against HBV: associated factors and determinants.

Authors:  Marianna Mastrodomenico; Mario Muselli; Luca Provvidenti; Maria Scatigna; Serena Bianchi; Leila Fabiani
Journal:  Hum Vaccin Immunother       Date:  2021-01-31       Impact factor: 3.452

7.  Current preventive policies and practices against Vaccine-Preventable Diseases and tuberculosis targeted for workers from hospitals of the Sardinia Region, Italy.

Authors:  M Campagna; F Argiolas; B Soggiu; N M Mereu; A Lai; M Galletta; R C Coppola
Journal:  J Prev Med Hyg       Date:  2016

8.  Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy.

Authors:  Guglielmo Dini; Alessandra Toletone; Ilaria Barberis; Nicoletta Debarbieri; Emanuela Massa; Chiara Paganino; Francesca Bersi; Alfredo Montecucco; Cristiano Alicino; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

9.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16

10.  Long-term persistency of hepatitis B immunity: an observational cross-sectional study on medical students and resident doctors.

Authors:  A Stefanati; N Bolognesi; F Sandri; G Dini; E Massa; A Montecucco; S Lupi; G Gabutti
Journal:  J Prev Med Hyg       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.